Tango Therapeutics Quarterly Cash Flow Statement
NASDAQ: TNGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
23.81+1.24 (+5.49%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tango Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Tango Therapeutics generated -$38.9 million of operating cash flow and spent $20,000 on capital expenditures. That left free cash flow of -$38.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Tango Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -55.34M | -45.51M | -38.75M | 15.88M | -38.85M | -39.88M | -37.67M | -29.17M | -25.55M | -37.91M | -30.76M | -22.26M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 425.00K | 463.00K | 479.00K | 555.00K | 625.00K | 622.00K | 620.00K | 622.00K | 632.00K | 625.00K | 617.00K | 613.00K |
| Stock-Based Compensation | 16.89M | 10.80M | 5.98M | 6.63M | 6.57M | 7.25M | 7.46M | 7.18M | 7.54M | 6.72M | 4.88M | 4.86M |
| Change in Working Capital | -5.95M | -514.00K | -881.00K | -55.81M | -5.17M | -3.11M | -7.51M | -9.80M | -8.40M | -5.07M | -4.16M | -13.81M |
| Operating Cash Flow | -38.87M | -44.36M | -29.72M | -30.95M | -36.52M | -41.70M | -36.65M | -33.39M | -23.61M | -37.86M | -27.47M | -31.14M |
| Capital Expenditures | 20.00K | 2.00K | -222.00K | -151.00K | -624.00K | -51.00K | -124.00K | -115.00K | -320.00K | -195.00K | -226.00K | -16.00K |
| Investing Cash Flow | -445.97M | 9.63M | -135.72M | 47.48M | 16.78M | 30.60M | 52.06M | 32.57M | 12.70M | -11.20M | 33.85M | -56.66M |
| Financing Cash Flow | 672.57M | 79.85M | 219.38M | 2.54M | 581.00K | 2.00K | 969.00K | 2.40M | 1.31M | 42.98M | 1.47M | 80.28M |
| Net Change in Cash | 187.73M | 45.12M | 53.94M | 19.07M | -19.16M | -11.10M | 16.38M | 1.58M | -9.60M | -6.08M | 7.85M | -7.52M |
| Free Cash Flow | -38.85M | -44.36M | -29.94M | -31.10M | -37.14M | -41.75M | -36.77M | -33.51M | -23.93M | -38.05M | -27.69M | -31.15M |
This table shows 12 quarterly periods of Tango Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TNGX's reporting calendar. What is a cash flow statement?